Faculty Profiles - NASU Yasutomo

Papers - NASU Yasutomo

Division display 481 - 500 of about 612 ／ All the affair displays >>

MP-453 1251シード線源による前立腺癌永久挿入密封小線源治療(一般演題ポスター,第94回日本泌尿器科学会総会)

江原伸, 真鍋大輔, 枝村康平, 谷本竜太, 小林知子, 雑賀隆史, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 97 ( 2 ) 480 - 480 2006

S11-6 密封小線源療法を施行された前立腺癌患者のQOLに関する研究 : 恥骨後式根治的前立腺摘除術とのProspectiveな比較において(シンポジウム11「限局性前立腺癌の治療成績とQOL」,第94回日本泌尿器科学会総会)

雑賀隆史, 江原伸, 真鍋大輔, 能勢宏幸, 枝村康平, 谷本竜太, 小林知子, 津島知靖, 那須保友, 中西代志子, 公文裕巳

日本泌尿器科学会雑誌 97 ( 2 ) 165 - 165 2006

Intracavernous injection of prostaglandin E-1 is effective in patients with erectile dysfunction not responding to phosphodiesterase 5 inhibitors Reviewed

A Nagai, N Kusumi, H Tsuboi, K Ishii, T Saika, Y Nasu, H Kumon

ACTA MEDICA OKAYAMA 59 ( 6 ) 279 - 280 2005.12

Language：English Publishing type：Research paper (scientific journal) Publisher：OKAYAMA UNIV MED SCHOOL

We report on 64 patients who did not achieve erections adequate for satisfactory sexual intercourse from among a total of 243 patients who were prescribed PDE5 inhibitors for erectile dysfunction (ED). Intracavernous injection (ICI) of PGE(1), was performed in this non-responder group. An ICI of 20 or 40 mcg of PGE(1) in 1 ml saline was performed and the responses evaluated. Forty-nine out of 64 (77%) cases responded to 20 mcg of PGE(1). Forty mcg of PGE(1) was injected into the 15 non-responding cases, and 9 patients responded favorably. The overall effective rate was 58/64 (91 %). No major adverse effects were observed.

Web of Science

researchmap

Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase Reviewed

F Abarzua, M Sakaguchi, M Takaishi, Y Nasu, K Kurose, S Ebara, M Miyazaki, M Namba, H Kumon, N Huh

CANCER RESEARCH 65 ( 21 ) 9617 - 9622 2005.11

Language：English Publishing type：Research paper (scientific journal) Publisher：AMER ASSOC CANCER RESEARCH

Alteration in genes which takes place during malignant conversion and progression could be potential targets for gene therapy. We previously identified REIC/Dkk-3 as a gene whose expression is reduced in many human cancers. Here, we showed that expression of REIC/Dkk-3 was consistently reduced in human prostate cancer tissues in a stage-dependent manner. Forced expression of REIC/Dkk-3 induced apoptosis in human prostate cancer cell lines lacking endogenous REIC/Dkk-3 expression but not in REIC/Dkk3-proficient normal prostate epithelial and stromal cells. The apoptosis involved c-jun-NH2-kinase activation, mitochondrial translocation of Bax, and reduction of Bcl-2. A single injection of an adenovirus vector carrying REIC/Dkk-3 showed a dramatic antitumor effect on a xenotransplanted human prostate cancer. Thus, REIC/Dkk-3 could be a novel target for gene-based therapy of prostate cancer.

DOI： 10.1158/0008-5472.CAN-05-0829

Web of Science

researchmap

Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute Reviewed

K Edamura, T Saika, T Senoh, F Koizumi, D Manabe, S Ebara, H Kaku, T Yokoyama, F Abarzua, A Nagai, Y Nasu, T Tsushima, H Kumon

ACTA MEDICA OKAYAMA 59 ( 5 ) 195 - 199 2005.10

Language：English Publishing type：Research paper (scientific journal) Publisher：OKAYAMA UNIV MED SCHOOL

This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA) failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100% for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81% 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93% and 100% cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79% rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease.

Web of Science

researchmap

当院における膀胱全摘除術の臨床統計

谷本竜太, 雑賀隆史, 枝村康平, 小林知子, 眞鍋大輔, 江原伸, 賀来春紀, 那須保友, 公文裕巳

西日本泌尿器科 67 ( 増刊 ) 148 - 148 2005.10

腎癌に対するCTガイド下経皮的ラジオ波治療(Radiofrequency Ablation) 15例の臨床的検討

小林知子, 眞鍋大輔, 江原伸, 生口俊浩, 郷原英夫, 賀来春紀, 雑賀隆史, 那須保友, 公文裕巳

日本癌治療学会誌 40 ( 2 ) 621 - 621 2005.9

125Iシード線源による前立腺癌永久挿入密封小線源治療

江原伸, 真鍋大輔, 谷本竜太, 枝村康平, 雑賀隆史, 那須保友, 公文裕巳

日本癌治療学会誌 40 ( 2 ) 736 - 736 2005.9

ホルモン抵抗性前立腺癌に対するドセタキセル,エストラムスチン,デキサメサゾン併用療法の臨床経験

真鍋大輔, 江原伸, 雑賀隆史, 小林知子, 枝村康平, 谷本竜太, 賀来春紀, 那須保友, 津島知靖, 公文裕巳

日本癌治療学会誌 40 ( 2 ) 739 - 739 2005.9

Adrenal myelolipoma treated by laparoscopic adrenalectomy: A report of two cases

Hiromu Tsuboi, Masami Watanabe, Osamu Fujita, Nobuyuki Kusaka, Takashi Senoh, Takashi Saika, Atsushi Nagai, Yasutomo Nasu, Hiromi Kumon

Nishinihon Journal of Urology 67 ( 9 ) 562 - 567 2005.9

Language：Japanese Publishing type：Research paper (scientific journal)

We herein report 2 cases of adrenal myelolipoma which were treated with laparoscopic adrenalectomy. In Case 1, a 46-year-old woman presented with right flank pain. A right adrenal mass was detected by abdominal ultrasonography. In Case 2, a 56-year-old woman presented with a cough. A right adrenal mass was incidentally detected by chest CT. In both cases, endocrine study of the adrenal cortex and medulla demonstrated normal results. According to ultrasonography, CT and MRI, each of the adrenal masses seemed most likely to be an adrenal myelolipoma. Adrenalectomy was performed by laparoscopic procedure. The tumor size was 6.5 × 6.0 × 6.0 cm and 4.5 × 3.5 × 3.0 cm in Cases 1 and 2, respectively. Histology showed a complex of hematopoietic and adipose tissues, corresponding to adrenal myelolipoma. In each case, the courses has been uneventful both during and after surgery. Laparoscopic adrenalectomy is recommended for the treatment of myelolipoma since earlier postoperative recovery can be expected compared with open surgery.

Scopus

researchmap

Clinical results of one-stage urethroplasty with parameatal foreskin flap for hypospadias Reviewed

A Nagai, Y Nasu, M Watanabe, N Kusumi, H Tsuboi, H Kumon

ACTA MEDICA OKAYAMA 59 ( 2 ) 45 - 48 2005.4

Language：English Publishing type：Research paper (scientific journal) Publisher：OKAYAMA UNIV MED SCHOOL

We investigated the usefulness of one-stage urethroplasty by the parameatal foreskin flap method (OUPF procedure), which is useful for repairing all types of hypospadias. Between June 1992 and March 2001, the OUPF procedure was performed on 18 patients with hypospadias: 10 patients with distal and 8 with proximal hypospadias. The follow-up periods ranged from 33-75 months, with an average of 52 months. The duration of surgery, the catheter indwelling period, and the postoperative complications of each patient were analyzed. The median age of the patients at the time of surgery was 3 years and 8 months. The length of surgery for OUPF II ranged from 150-230 min (average 186 min), and from 190-365 min (average 267 min) for OUPF IV. Postoperative complications were confirmed in 3 of the 18 patients (16.6%). Two patients had fistulas, and one had a meatal regression. The fistulas were successfully closed by the simple multilayered closure method. After adopting DuoDerm dressings instead of elastic bandages for protection of the wound, no fistulization occurred. DuoDerm dressings are useful in the healing of wounds without complications. To date, the longest follow-up period has been 75 months, and during that time there have been no late complications such as urethral stenosis or penile curvature. OUPF is a useful method in the treatment of hypospadias with a low incidence of early and late complications.

Web of Science

researchmap

Predicting postoperative renal insufficiency in patients undergoing nephrectomy for renal malignancy: Assessment by renal scintigraphy using (99m)Technetium-mercaptoacetyltriglycine Reviewed

Y Shirasaki, T Saika, T Tsushima, Y Nasu, R Arata, H Kumon

JOURNAL OF UROLOGY 173 ( 2 ) 388 - 390 2005.2

Language：English Publishing type：Research paper (scientific journal) Publisher：LIPPINCOTT WILLIAMS & WILKINS

Purpose: We performed 99(m)Tc-mercaptoacetyltriglycine (MAG3) renal scintigraphy in patients with renal malignancy to evaluate the function of each renal unit before and after nephrectomy to see if postoperative functional deterioration could be predicted based on scintigraphy results and creatinine clearance.
Materials and Methods: A total of 22 men and 13 women with renal malignancy, including 32 with renal cell carcinoma and 3 with urothelial cancer, were prospectively enrolled in this study. Average patient age was 64.3 years (median 65, range 43 to 88). All patients underwent MAG3 renal scintigraphy before and after unilateral nephrectomy. At the same time serum creatinine and endogenous creatinine clearance were determined.
Results: Mean serum creatinine was 0.93 mg/dl before and 1.31 after nephrectomy (p <0.0001). Preoperative endogenous creatinine clearance was 70.8 ml per minute per 1.73 m(2), which decreased to 49.0 ml per minute per 1.73 m(2) after nephrectomy (p <0.0001). Mean MAG3 clearance of the remaining kidney increased 35.1% above baseline from 156.5 to 211.5 ml per minute per 1.73 m(2) following nephrectomy. Spearman rank core analysis revealed that preoperative MAG3 clearance of the remaining kidney significantly correlated with postoperative creatinine clearance (r = 0.596, p = 0.0005). Preoperative MAG3 clearance of the remaining kidney more than 130 ml per minute per 1.73 M-2 coincided with postoperative creatinine clearance above 40 ml per minute per 1.73 m(2).
Conclusions: MAG3 renal scintigraphy may be useful for predicting renal insufficiency after nephrectomy. The findings in this study suggest that preoperative MAG3 clearance of the remaining kidney less than 130 ml per minute per 1.73 m(2) is a risk factor for postoperative renal insufficiency.

DOI： 10.1097/01.ju.0000149980.61593.5f

Web of Science

researchmap

Varicocele rupture due to sexual intercourse

Nishiyama Y, Nagai A, Nasu Y, Watanabe M, Kusumi N, Monden K, Kumon H

Int J Urol 12 585 - 587 2005

Sex reassignment surgery for male to female transsexuals: initial experience in Okayama university hospital.

Atsushi Nagai, Eijirou Tokuyama, Yuzaburo Nanba, Tetsuya Tsutsui, Yoshihiro Kimata, Mikiya Nakatsuka, Isao Koshima, Takashi Saika, Yasutomo Nasu, Hiromi Kumon

Acta medica Okayama 59 ( 5 ) 231 - 233 2005

Language：English Publishing type：Research paper (scientific journal)

The first case of sex reassignment surgery (SRS) in our hospital was performed in January 2001; as of February, 2005, 4 cases of MTF-SRS had been performed. In the 2 most recent cases, we used penile and scrotal skin flaps to avoid complications. The depth and width of the new vagina was made to be adequate for sexual intercourse. Future attention should be focused on devising a surgical technique that will help prevent the complications of partial necrosis of the epidermal skin and wound dehiscence. Although ours is only an initial experience, we describe our surgical technique herein.

PubMed

researchmap

Adeno-associated virus-mediated human IL-10 gene transfer suppresses the development of experimental autoimmune orchitis

Watanabe M, Kashiwakura Y, Kusumi N, Tamayose K, Nasu Y, Nagai A, Shimada T, Daida H, Kumon H

Gene Therapy 12 1126 - 1132 2005

Minimal invasiveness and effectivity of subinguinal microscopic varicocelectomy:A comparative study with retroperitoneal high and laparoscopic approaches

Watanabe M, Nagai A, Kusumi N, Tsuboi H, Nasu Y, Kumon H

Int J Urol 12 892 - 898 2005

Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study.

Toyoaki Uchida, Shiro Baba, Akira Irie, Shigehiro Soh, Naoya Masumori, Taiji Tsukamoto, Hiroomi Nakatsu, Hiroyuki Fujimoto, Tadao Kakizoe, Takeshi Ueda, Tomohiko Ichikawa, Nobutaka Ohta, Tadaichi Kitamura, Makoto Sumitomo, Masamichi Hayakawa, Teiichiro Aoyagi, Masaaki Tachibana, Ryusuke Ikeda, Kohji Suzuki, Nobuo Tsuru, Kazuo Suzuki, Seiichiro Ozono, Kiyohide Fujimoto, Yoshihiko Hirao, Kohichi Monden, Yasutomo Nasu, Hiromi Kumon, Kazuhiko Nishi, Shoichi Ueda, Hirofumi Koga, Seiji Naitoh

Hinyokika kiyo. Acta urologica Japonica 51 ( 10 ) 651 - 658 2005

Language：English Publishing type：Research paper (scientific journal)

We report a multicenter trial with transrectal high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. A total of 72 consecutive patients with stage T1c-2NOM0 prostate cancer were treated using the Sonablate 500TM HIFU device (Focus Surgery, Indianapolis, USA). Biochemical recurrence was defined according to the criteria recommended by the American Society for Therapeutic Radiology and Oncology Consensus Panel. The median age and prostate specific antigen (PSA) level were 72 years and 8.10 ng/ml, respectively. The median follow-up period for all patients was 14.0 months. Biochemical disease-free survival rates in all patients at 1 and 2 years were 78% and 76%, respectively. Biochemical disease-free survival rates in patients with stage T1c, T2a and T2b groups at 2 years were 89, 67% and 40% (p = 0.0817). Biochemical disease-free survival rates in patients with Gleason scores of 2-4, 5-7 and 8-10 at 2 years were 88, 72% and 80% (p = 0.6539). Biochemical disease-free survival rates in patients with serum PSA of less than 10 ng/ml and 10-20 ng/ml were 75% and 78% (p = 0.6152). No viable tumor cells were noted in 68% of patients by postoperative prostate needle biopsy. Prostatic volume was decreased from 24.2 ml to 14.0 ml at 6 months after HIFU (p < 0.01). No statistically significant differences were noted in International Prostate Symptom Score, maximum urinary flow rate and quality of life analysis with Functional Assessment of Cancer Therapy. HIFU therapy appears to be minimally invasive, efficacious and safe for patients with localized prostate cancer with pretreatment PSA levels less than 20 ng/ml.

PubMed

researchmap

Analysis of human ejaculation using color doppler ultrasonography:A comparison between antegrade and retrograde ejaculation

Nagai A, Watanabe M, Nasu Y, Iguchi H, Kusumi N, Kumon H

Urology 65 ( 2 ) 365 - 368 2005

Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. International journal

Masami Watanabe, Yasutomo Nasu, Yuji Kashiwakura, Norihiro Kusumi, Kenji Tamayose, Atsushi Nagai, Tetsuo Sasano, Takashi Shimada, Hiroyuki Daida, Hiromi Kumon

Human gene therapy 16 ( 6 ) 699 - 710 2005

Language：English Publishing type：Research paper (scientific journal)

Maspin is a member of the serine protease inhibitors and the maspin gene, a tumor suppressor gene, is down-regulated in a large fraction of prostate cancers. We evaluated the use of adeno-associated virus (AAV, serotype 2) vector encoding maspin as a means for in vivo gene therapy for human prostate cancer. TUNEL assay of subcutaneously formed LNCaP or DU145 tumors in nude mice showed that intratumoral AAV-mediated maspin expression significantly upregulated the number of apoptotic cells compared with AAV-LacZ treatment. Immunofluorescence double staining for maspin protein and apoptosis in LNCaP tumors showed that the percentage of apoptotic cells in AAV-maspin-mediated maspin-expressing cells was significantly high compared with that in AAV-GFP-mediated GFP-expressing cells. Moreover, significantly fewer CD31-positive microvessels were observed in AAV-maspin-treated tumors compared with the control tumors. These therapeutic responses were highly correlated to persistent maspin expression in tumors, confirmed by Western blot analysis until at least day 56 after treatment. Finally, intratumoral delivery of AAV-maspin significantly suppressed growth of LNCaP and DU145 tumors and improved survival of mice. We conclude that AAV-mediated prolonged maspin expression efficiently suppresses human prostate tumor growth in vivo by apoptosis induction and inhibition of angiogenesis.

PubMed

researchmap

XAGE-1 rnRNA expression in prostate cancer and antibody response in patients Reviewed

F Koizumi, Y Noguchi, T Saika, K Nakagawa, S Sato, AMA Eldib, Y Nasu, H Kumon, E Nakayama

MICROBIOLOGY AND IMMUNOLOGY 49 ( 5 ) 471 - 476 2005

Language：English Publishing type：Research paper (scientific journal) Publisher：CENTER ACADEMIC PUBL JAPAN

To evaluate the feasibility of cancer vaccine targeting XAGE-1, we investigated the expression of 4 XAGE-1 transcript variants and the humoral immune response to XAGE-1 in prostate cancer patients. XAGE-1a, b, c, d mRNA expression was analyzed in 54 prostate cancer specimens and 8 specimens of benign prostate hypertrophy (BPH) by reverse transcription-polymerase chain reaction (RT-PCR). The Immoral response to XAGE-1 was investigated in sera obtained from 278 patients with prostate cancer and 40 healthy volunteers by enzyme-linked immunosorbent assay (ELISA) using recombinant protein. XAGE-1b mRNA expression was observed in 14 of 54 (26%) prostate cancer specimens, while XAGE-1a, c, and d mRNA expressions were observed in 1, 1, and 3, respectively. None of the 4 XAGE-1 transcript variants was observed in the 8 BPH specimens. Antibody against XAGE-1 was detected in sera from 2 of 129 stage D2 patients, whereas none of sera from 149 patients with localized prostate cancer or lymph node metastasis had detectable XAGE-1 antibody. No reactivity to XAGE-1 was found in sera from the 40 healthy individuals.

Web of Science

researchmap

　 PREV - NEXT 　

< NASU Yasutomo >

Papers - NASU Yasutomo